Drugs / PLH-2301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07390552 | May 2026 → Jun 2027 expected | pelvic muscle wasting | Pluto Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLH-2301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07390552 ↗ |
| Route | Oral | “PLH-2301 administered orally according to assigned dosing regimen.” NCT07390552 ↗ |